Nalbuphine Versus Morphine for Perioperative Tumor Ablation

• Status: Recruiting
• Trial end date: 2023-08-31
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, positive control, multicentre trial is designed to compare the analgesic efficacy and safety of nalbuphine hydrochloride injection and morphine hydrochloride injection for perioperative tumor ablation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongda Hospital
• Treatments: Morphine; Nalbuphine

Criteria

Inclusion Criteria:

• Patients requiring tumor ablation;

• Voluntarily participate and sign the informed consent.

Exclusion Criteria:

• Allergic to contrast agent, test drug or other ingredients;

• With a history of substance abuse, chronic pain and mental illness;

• Use of any monamine oxidase inhibitor within 14 days prior to randomization;

• Pregnant or breastfeeding;

• Cannot tolerate ablation due to other reasons;

• Cannot express their wishes correctly;

• Poor compliance, unable to complete the trial;

• Have participated in other drug trials within 30 days prior to enrollment;

• Judged by the researcher to be unsuitable.